TWI562777B - Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury - Google Patents
Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injuryInfo
- Publication number
- TWI562777B TWI562777B TW103124615A TW103124615A TWI562777B TW I562777 B TWI562777 B TW I562777B TW 103124615 A TW103124615 A TW 103124615A TW 103124615 A TW103124615 A TW 103124615A TW I562777 B TWI562777 B TW I562777B
- Authority
- TW
- Taiwan
- Prior art keywords
- hepes
- piperazine
- reversal
- hydroxy
- role
- Prior art date
Links
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 title 2
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24346409P | 2009-09-17 | 2009-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201440769A TW201440769A (zh) | 2014-11-01 |
| TWI562777B true TWI562777B (en) | 2016-12-21 |
Family
ID=43757159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103124615A TWI562777B (en) | 2009-09-17 | 2010-09-17 | Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
| TW099131755A TWI494106B (zh) | 2009-09-17 | 2010-09-17 | Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW099131755A TWI494106B (zh) | 2009-09-17 | 2010-09-17 | Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8883855B2 (OSRAM) |
| EP (3) | EP2477626A4 (OSRAM) |
| JP (4) | JP2013505264A (OSRAM) |
| KR (1) | KR101737775B1 (OSRAM) |
| CN (4) | CN103977405A (OSRAM) |
| AR (1) | AR078290A1 (OSRAM) |
| AU (1) | AU2010295445B2 (OSRAM) |
| BR (1) | BR112012006155A2 (OSRAM) |
| CA (3) | CA2774375C (OSRAM) |
| HK (1) | HK1199621A1 (OSRAM) |
| IL (2) | IL264055B2 (OSRAM) |
| IN (1) | IN2012DN02499A (OSRAM) |
| MX (2) | MX360190B (OSRAM) |
| MY (2) | MY159626A (OSRAM) |
| NZ (1) | NZ598861A (OSRAM) |
| SG (3) | SG179191A1 (OSRAM) |
| TW (2) | TWI562777B (OSRAM) |
| WO (1) | WO2011035212A2 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103977405A (zh) | 2009-09-17 | 2014-08-13 | 北德克萨斯医学联合会 | N-2-羟基-乙基-哌嗪-n’-2-乙磺酸（hepes）在疼痛控制和脱髓鞘损伤逆转中的作用 |
| ES2851678T3 (es) | 2014-07-21 | 2021-09-08 | Glia Llc | Método para el tratamiento de deterioro cognitivo o emocional asociado con la radioterapia y quimioterapia con cannabinoides |
| CA2984379C (en) * | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI494106B (zh) * | 2009-09-17 | 2015-08-01 | North Texas Medical Ass | Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| ATE207074T1 (de) | 1995-07-06 | 2001-11-15 | Fraunhofer Ges Forschung | Thiolsilane, verfahren zu deren herstellung und deren verwendung |
| US5716959A (en) * | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
| ES2392391T3 (es) * | 1998-02-11 | 2012-12-10 | Bhi Limited Partnership | Método para modular la activación de macrófagos |
| CA2585983C (en) | 2004-11-10 | 2014-03-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| EP2011491A1 (en) | 2007-07-05 | 2009-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticonvulsive pharmaceutical compositions |
| EP2167068A2 (en) * | 2007-07-05 | 2010-03-31 | Inserm-Institut National De La Sante Et De La Recherche Medicale | Anticonvulsive pharmaceutical compositions |
| EP2163246A1 (en) * | 2008-09-12 | 2010-03-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin |
| JP2013504151A (ja) | 2009-09-04 | 2013-02-04 | ビーエーエスエフ ソシエタス・ヨーロピア | 色素増感太陽電池 |
| AU2014206220B2 (en) | 2009-09-17 | 2016-09-29 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
-
2010
- 2010-09-17 CN CN201410166019.3A patent/CN103977405A/zh active Pending
- 2010-09-17 AR ARP100103407A patent/AR078290A1/es unknown
- 2010-09-17 MX MX2015008916A patent/MX360190B/es unknown
- 2010-09-17 US US12/885,404 patent/US8883855B2/en active Active
- 2010-09-17 IL IL264055A patent/IL264055B2/en unknown
- 2010-09-17 CA CA2774375A patent/CA2774375C/en active Active
- 2010-09-17 EP EP10817952.4A patent/EP2477626A4/en not_active Withdrawn
- 2010-09-17 EP EP19161338.9A patent/EP3520794A3/en active Pending
- 2010-09-17 SG SG2012018842A patent/SG179191A1/en unknown
- 2010-09-17 CN CN201811365002.5A patent/CN109224077A/zh active Pending
- 2010-09-17 KR KR1020127009683A patent/KR101737775B1/ko active Active
- 2010-09-17 MY MYPI2012001195A patent/MY159626A/en unknown
- 2010-09-17 MX MX2012003212A patent/MX2012003212A/es active IP Right Grant
- 2010-09-17 JP JP2012529955A patent/JP2013505264A/ja active Pending
- 2010-09-17 TW TW103124615A patent/TWI562777B/zh active
- 2010-09-17 AU AU2010295445A patent/AU2010295445B2/en active Active
- 2010-09-17 CA CA3122553A patent/CA3122553A1/en active Pending
- 2010-09-17 CN CN201710494640.6A patent/CN107260740A/zh active Pending
- 2010-09-17 MY MYPI2015002505A patent/MY174012A/en unknown
- 2010-09-17 CA CA2977918A patent/CA2977918C/en active Active
- 2010-09-17 BR BR112012006155A patent/BR112012006155A2/pt not_active Application Discontinuation
- 2010-09-17 CN CN2010800521032A patent/CN102612366A/zh active Pending
- 2010-09-17 TW TW099131755A patent/TWI494106B/zh active
- 2010-09-17 SG SG10201500510YA patent/SG10201500510YA/en unknown
- 2010-09-17 NZ NZ598861A patent/NZ598861A/xx unknown
- 2010-09-17 SG SG10202100421XA patent/SG10202100421XA/en unknown
- 2010-09-17 EP EP14191925.8A patent/EP2835133B1/en active Active
- 2010-09-17 WO PCT/US2010/049405 patent/WO2011035212A2/en not_active Ceased
-
2012
- 2012-03-15 IL IL218677A patent/IL218677B/en active IP Right Grant
- 2012-03-22 IN IN2499DEN2012 patent/IN2012DN02499A/en unknown
-
2014
- 2014-09-09 US US14/481,582 patent/US9867820B2/en active Active
- 2014-11-14 JP JP2014231168A patent/JP5974062B2/ja active Active
-
2015
- 2015-01-06 HK HK15100074.2A patent/HK1199621A1/xx unknown
- 2015-02-10 JP JP2015024177A patent/JP2015129150A/ja active Pending
-
2016
- 2016-07-15 JP JP2016140167A patent/JP6347807B2/ja active Active
-
2017
- 2017-10-04 US US15/725,007 patent/US10213425B2/en active Active
-
2019
- 2019-01-14 US US16/247,233 patent/US20190142825A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI494106B (zh) * | 2009-09-17 | 2015-08-01 | North Texas Medical Ass | Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2232670A4 (en) | INTELLIGENT BATTERY SYSTEM AND METHODS OF USE | |
| IL248955A0 (en) | Adherent cells from adipose tissue or placenta for use in healing | |
| PL2318033T3 (pl) | Kompozycje do leczenia bólu i/lub stanu zapalnego | |
| HUE041510T2 (hu) | Biológiai sejtek és szövetek krioprezervációja | |
| EP2432462A4 (en) | OXYGEN PROCEDURE AND COMPOSITIONS FOR THE TREATMENT OF MAMMALIAN DISEASES | |
| EP2282746A4 (en) | COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING | |
| PT2142186E (pt) | Utilização de oligómeros de ácido láctico no tratamento de infeções ginecológicas | |
| ZA201202151B (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
| EP2400980A4 (en) | THERAPEUTIC VISCATINIUM AGENTS FOR THE TREATMENT OF ACNE AND OTHERS | |
| IL200549A0 (en) | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | |
| ZA200905688B (en) | Fungicidal mixtures of 1-Methylpyrazole-4-Ylcarboxylic acid anilides and azolopy-rimidinylamines | |
| PL2323644T3 (pl) | N-podstawione benzenopropanoamidowe lub benzenopropanoamidowe pochodne do zastosowania w leczeniu bólu | |
| GB0719777D0 (en) | Improvements in and relating to medical devices | |
| TWI562777B (en) | Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury | |
| ZA201001415B (en) | Sex-peptides resistant to proteolytic degradation and their use in biological control of insects | |
| PT2475361T (pt) | Derivados de benzenopropanamidas substituídas em n, para serem utilizadas no tratamento de dor e de inflamação | |
| PL2459721T3 (pl) | Udoskonalony system ekspresji ludzkiej długiej pentraksyny i jego zastosowania | |
| GB0821594D0 (en) | Improvements in or relating to the treatment of tissue damage | |
| GB2456389B (en) | Pharmaceutical and skin compositions comprising emulsifying ointment and water | |
| GB0809199D0 (en) | Improvement in and relating to animal stalls | |
| GB0722649D0 (en) | Improvements in and relating to the consideration of evidence | |
| GB0703577D0 (en) | Improvements in and relating to drainage | |
| IL203609A (en) | Peptides sex are resistant to proteolytic decomposition and their use in insect biological control | |
| FI20070921A0 (fi) | Lukittuvan ponttiliitoksen käyttö eristyskourun pituussuuntaisessa liitoksessa |